We have reported that TNF, a pro-inflammatory cytokine present in several lung pathologies, decreases the expression and activity of the epithelial Na + channel (ENaC) by ~70% in alveolar epithelial cells. Because dexamethasone has been shown to upregulate ENaC mRNA expression, and is well-known to downregulate pro-inflammatory genes, we tested if it could alleviate the effect of TNF on ENaC expression and activity. In co-treatment with TNF, we found that dexamethasone reversed the inhibitory effect of TNF and upregulated , and ENaC mRNA expression. When the cells were pre-treated for 24 h with TNF prior to co-treatment, dexamethasone was still able to increase ENaC mRNA expression to 1.8-fold
Introduction
Active Na + absorption by polarized lung alveolar epithelial cells is the main driving force of lung liquid clearance at birth and lung edema clearance in adulthood. Vectorial Na + gating at the apical membrane and its extrusion by Na + /K + -ATPase at the basolateral side create osmotic pressure that drives water from the alveoli to the interstitium (5; 56). Although several types of Na + channels and co-transporters are expressed in alveolar epithelial cells (54), experimental evidence indicates that the epithelial sodium channel (ENaC) plays a prominent role in the lung liquid clearance process. This channel is composed of 3 related subunits ( , , ) (11; 12) that are expressed in the lung from alveoli to the nasal epithelium (10; 27; 55). Inactivation of Dexamethasone (Dex) is a synthetic steroid that has been shown to upregulate ENaC expression via a very conserved glucocorticoid regulatory element (GRE) in its promoter (15; 17; 63; 74) . Dexamethasone is also a well-known anti-inflammatory agent that has been used or proposed as a therapeutic approach to inflammatory disease, including lung injury (29). It exerts its anti-inflammatory effect by repressing NF-B and AP-1 pro-inflammatory gene stimulation (48). For all these reasons, we tested here if dexamethasone could alleviate the impact of TNF on ENaC expression in alveolar epithelial cells. First, the modulation of , and ENaC mRNA expression was studied by Northern blotting in alveolar epithelial cells treated with TNF and dexamethasone. The consequence of such co-treatment on ENaC promoter activity was then evaluated after transient transfection of a plasmid where the ENaC promoter was driving luciferase (Luc) gene expression. To complete our study, we investigated the impact of these treatments on transepithelial and apical membrane amiloride-sensitive current generated by the cells as well as the liquid clearance ability of cell monolayers.
Altogether, our results revealed that dexamethasone in co-treatment with TNF normalizes ENaC expression and activity in alveolar epithelial cells.
Materials and methods

Alveolar epithelial cell isolation and experimental conditions
Alveolar epithelial cells were isolated from male Sprague-Dawley rats as described previously and according to a procedure approved by our institutional animal care committee (17). Perfused lungs were digested with elastase, and the cells purified by a differential adherence technique on bacteriological plastic plates coated with rat IgG (17). The cells were maintained in minimum essential medium (MEM)(Invitrogen, Burlington, Ontario, Canada)
containing 10% FBS (Invitrogen), 0.08 mg/l gentamicin, 0.2% NaHCO 3 , 0.01 M HEPES and 2 mM L-glutamine. They were plated at 4 X 10 5 cells/cm 2 density in 25 cm 2 plastic flasks or at 1 X 10 6 cells/cm 2 on polycarbonate filters (Costar Transwell, Toronto, Ontario, Canada) and cultured at 37°C with 5% CO 2 in a humidified incubator. The medium was supplemented with Septra (3 µg/ml trimethoprim and 17 µg/ml sulfamethoxazole) for the first 3 days. After this time, the medium was replaced, and the cells cultured without Septra.
Northern blotting
To study the influence of TNF and dexamethasone on the ENaC steady state mRNA level, alveolar epithelial cells cultured for 3 days were treated with 100 ng/ml recombinant mouse TNF (Calbiochem, La Jolla, CA, USA) for 6, 8 or 24 h in the presence or absence of 100 nM dexamethasone. Total RNA from these cells was extracted by a modification of the guanidinium-phenol technique (19). For Northern blotting, 10 µg of total RNA were electrophoresed on 1% agarose-formaldehyde gel and transferred to GeneScreen nylon membranes (NEN, Boston, MA, USA) after overnight blotting with 10 X SSC. Hybridization was performed, as reported previously, in Church buffer (0.5 M Na phosphate, pH 7.2, 7% SDS (w/v), 1 mM EDTA, pH 8) (19). The nylon membranes were hybridized successively with a 764-bp mouse ENaC cDNA probe (his-445 to stop codon) (19), a 1403-bp rat ENaC probe (ATG to trp-486 ), a 1794-bp rat ENaC probe (gly-141 to 3'-UTR) and, finally, with a 18S rRNA probe consisting of a 640-bp fragment cloned from nt 852 to 1492 of rat 18S rRNA after reverse transcription-polymerase chain reaction (RT-PCR) amplification (17). The Northern blots were scanned and analyzed in a Typhoon PhosphorImager (Molecular Dynamics, Sunnyvale, CA, USA). mRNA expression was always compared to matching untreated cells for each time period of the study. For reproducibility and statistical reasons, Northern blotting was repeated several times with RNA extracted from cells isolated from different rats. At least 3 animals (n=3)
were used for each time point.
Transient transfection and Luc assay
The modulation of ENaC promoter activity by 100 ng/ml TNF, 100 nM dexamethasone (Dex) and TNF+Dex co-treatment was tested in A549 cells, a human alveolar epithelial cell line.
The cells were transiently transfected with a 2.9-kb BamHI-MscI fragment of the mouse ENaC promoter (17) ( ENaC-Luc) cloned upstream of the Luc reporter gene. A 1.17-kb GRE deletion mutant ( ENaC GRE) not responding to dexamethasone was also tested. The generation of these constructs was described previously (31). In some experiments, the pHH-Luc plasmid with a MMTV promoter highly responding to dexamethasone treatment (57) was also incubation at room temperature, the mix was added drop by drop to the cells. After 6 h of transfection, the cells were rinsed and fresh medium was added containing or not 100 ng/ml TNF, 100 nM dexamethasone or both combined for 24 h. Firefly and Renilla luciferase assays were undertaken with the Dual-Luciferase Reporter Assay System as specified by the manufacturer (Promega). Luminometry measurements were performed in a Turner TB/2020 luminometer. For response curves, the cells were incubated with 0, 1, 2.5, 10 or 25 nM dexamethasone in the presence or absence of 100 ng/ml TNF. 10 µM RU-486, an antagonist of the glucocorticoid receptor (GR), was tested in some transfections.
Cytokine detection in the medium
The profiles of cytokines secreted in the conditioned medium of TNF-treated cells were investigated with a ''protein array'' approach using a rat cytokine array (rat cytokine array I, RayBiotech Inc., Norcross, GA, USA) which enables the simultaneous detection of 19 cytokines.
The apical and basolateral media of control, TNF and TNF + dexamethasone treated cells were collected after 24-h stimulation. After 10-min 2800 g centrifugation, the supernatants were incubated overnight at 4 o C with the membranes. The membranes were then incubated sequentially with biotinylated-antibodies and labelled streptavidin before being revealed by chemiluminescence according to the manufacturer's protocol. The membranes were exposed for different time periods to Kodak X-omat AR which was developed with a film processor.
Electrophysiology
The impact of TNF on the electrophysiology of alveolar epithelial cells was studied, as reported previously (17) PCR amplifications for ENaC and -actin were performed side by side. The reactions were stopped after 19 and 14 cycles respectively when amplification was still in the exponential phase. 10 µl of the reactions were run on 1% agarose gel. After electrophoresis, the gels were stained by ethidium bromide, and the amplified products were quantified by scanning with a Typhoon fluorescence scanner (Molecular Dynamics). The results were reported as % of control expression after normalization with the -actin signal. The experiments were repeated 4 times (n=4) for every condition tested on alveolar epithelial cells purified from different animals. Monolayers with Pp > 3% were discarded. Free
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-I, measured in the presence of 20% trichloroacetic acid, was lower than 2.5%. Evaporative loss of fluid measured in a parafilmsealed Transwell membrane was nil. In parallel with each experiment, the cells were treated with 100 ng/ml TNF, 100 nM dexamethasone, 100 ng/ml TNF + 100 nM dexamethasone and 10 µM amiloride to also test the importance of amiloride-insensitive transport in the process. Filters of at least 6 animals (n 6) were tested for each condition.
Statistics
The data are presented as means ± SE. 
Results
Dexamethasone inhibits the effect of TNF on ENaC expression
ENaC mRNA expression was studied in primary alveolar epithelial cells treated for 6, 8 or 24 h with 100 ng/ml TNF in the presence and absence of 100 nM dexamethasone. As shown previously (18), TNF gradually decreased ENaC mRNA expression to ~30% of untreated cells at 24 h (Fig. 1) . Dexamethasone raised, at every time point studied, the level of ENaC transcript to ~4.5-fold of the untreated controls (Fig. 1) . In co-treatment experiments, dexamethasone in the presence of TNF was still able to increase ENaC transcript expression by 3.2-fold compared to the controls (Fig. 1) . and ENaC mRNA expressions were also investigated at the 24-h time point. TNF downregulated the expression of both subunits to ~30%
and 9% respectively (Fig. 1) . Although the increase induced by dexamethasone was smaller than for ENaC, in co-treatment experiments, the expression of and ENaC mRNA was maintained to 1.7-fold and 1.1-fold respectively, compared to the controls ( 
Effect of TNF and dexamethasone on ENaC promoter activity
To study the effect of TNF on ENaC promoter activity in the presence and absence of dexamethasone, A549 alveolar epithelial cells were transfected with ENaC-Luc, a construct where a 2.9-kb ENaC promoter fragment was cloned upstream of the firefly Luc reporter gene.
TNF decreased Luc expression by ~25% upon 24-h treatment (p<0.05) (Fig. 3A) . As reported previously (17), dexamethasone induced a 5-fold increase in Luc activity ( Fig. 3A ) (p<0.05), but was reduced to 2.77-fold when the cells were exposed to TNF+Dex co-treatment (Fig. 3A ).
Despite such a decrease, dexamethasone was still able to raise ENaC promoter activity above control cell values (p<0.05) (Fig. 3A) . Transfection of ENaC GRE-Luc, a 1.17-Kb deletion mutant not responding to dexamethasone because of the absence of GRE (Fig. 3B ), or the use of RU-486 (mifepristone), a steroid receptor antagonist ( 
Dexamethasone concentration required to reverse the effect of TNF on ENaC expression
Dose response curves of ENaC promoter activity at different dexamethasone concentrations are presented ( Stimulation by dexamethasone was significantly lower in the presence of TNF (p<0.05).
However, a 1.65-nM dexamethasone concentration was sufficient to normalize ENaC mRNA expression in the presence of TNF (Fig. 4B ).
Effect of dexamethasone on the cytokine secretion of alveolar epithelial cells treated with TNF
Dexamethasone is a known anti-inflammatory agent that downregulates the production of cytokines by its inhibition of NF-B signaling (48). To test the nature of the pro-inflammatory cytokines secreted in TNF-treated cells and to determine if dexamethasone could downregulate such secretion, the apical and basolateral media of cells treated with TNF were tested for their cytokine levels, using a ''protein array'' approach. While no cytokine could be detected in fresh, unconditioned medium, a few cytokines, including MCP-1 (Ccl2), were found to be secreted in the apical conditioned medium from control alveolar epithelial cells (Table I) . TNF increased the secretion in apical medium of MIP-3 (Ccl20) and Cinc-3 compared to untreated cells (Table I) .
Dexamethasone had no effect on the apical cytokine expression profile of TNF conditioned medium ( Table I) . The cytokine profile in basolateral conditioned medium was slightly different, since several cytokines present at the apical side could not be detected (Table I) . Compared to untreated cells, there was an increase of MIP-3 , fractalkine, Cinc-3 and LIX with TNF treatment (Table I) . While dexamethasone reduced fractalkine secretion and slightly decreased Cinc-3 and LIX in the basolateral medium of TNF-treated cells, the steroid had no other significant effect on the cytokine profile of TNF-conditioned medium.
Amiloride-sensitive current at the apical membrane after dexamethasone and TNF treatment
The presence of active ENaC at the apical membrane was evaluated in a Ussing chamber after amphotericin B permeabilization of the basolateral membrane (Fig. 5 ). In the conditions tested, NMDG-Cl replaced ~82% of Na + in the basolateral solution, creating an apical to basolateral Na + gradient. In these conditions, TNF decreased amiloride-sensitive current (ENaC current) to 22% of the controls (p<0.05) (Fig. 6 ). In dexamethasone-treated cells, ENaC current was increased to 198% (p<0.05), whereas in TNF+Dex-treated cells, it was augmented to 143% (Fig. 6 ). Clearly, dexamethasone treatment upregulates Na + channel activity at the apical membrane and can overcome the reduction evoked by TNF.
Open circuit measurement and liquid clearance ability of TNF+Dex-treated cells
The effects of TNF and dexamethasone treatments were also evaluated in open circuit configuration to study the impact of these conditions on the transepithelial characteristics of the monolayers (Table II) . In control cells, 1 µM amiloride-sensitive current represents 57% of total I te (Table II) . TNF treatment decreased amiloride-sensitive current to 27% of the controls (p<0.05) (Fig. 7A ) and also reduced R te from 1601 /cm 2 to 1313 /cm 2 (p<0.05)( Table II) .
Although dexamethasone treatment increased the current only very modestly to 116% of the controls (p<0.05) (Fig. 7A ) in TNF+Dex co-treatment it inhibited the effect of TNF, allowing the current to be maintained at 112% of the controls (p<0.05) (Fig. 7A) . Because transepithelial Na Dexamethasone treatment had no impact on paracellular permeability, and could not decrease the permeability induced by TNF (data not included).
Discussion
In this study, we tested if dexamethasone could inhibit the effect of TNF on ENaC expression and activity in alveolar epithelial cells. We found that dexamethasone in cotreatment could indeed increase ENaC promoter activity and mRNA expression in TNF-treated cells and was able to normalize ENaC transepithelial current as well as the liquid clearance ability of the cell monolayers.
Dexamethasone at a 100-nM concentration could heighten ENaC mRNA expression by ~4. They suggest that in TNF-treated cells, dexamethasone reverses the effects of TNF on genes that are not involved in inflammatory response, but are important for lung epithelial functions.
In addition to its modulation of ENaC promoter activity and ENaC mRNA expression in
TNF treated cells, we tested how dexamethasone could alleviate the effect of the cytokine on the Na + transport abilities of alveolar epithelial cells. The proportion of active ENaC channel at the apical membrane was evaluated in Ussing chamber after amphotericin B permeabilization of the basolateral membrane in the presence of a Na + gradient. In these conditions, we found that TNF reduced amiloride-sensitive I sc at the membrane by about 78%. We reported previously that TNF had no significant impact on Na + /K + -ATPase activity (18). The results presented here confirm that TNF greatly reduces the ENaC current at the apical membrane. Although the amount of membrane-associated ENaC subunits was not measured, the amphotericin B experiment allowed us to determine the current generated by ENaC at the apical membrane.
TNF, by decreasing ENaC protein and mRNA expression (18), could affect the amount of active channel at the membrane. The cytokine could also affect insertion and retrieval of the channel at the membrane as well as the activation of silent channels. Although the experimental design used in permeabilization experiments does not allow us to determine the exact mechanism leading to such decrease, it is possible that low expression of ENaC at the mRNA and protein levels could be involved in the reduction of ENaC current in TNF-treated cells.
Dexamethasone augmented ENaC activity at the apical membrane by ~2-fold compared to untreated cells. This increase was smaller than the rise in ENaC mRNA, probably because the number of active channels at the membrane is not only the result of transcription, but also of translation (62; 64) as well as membrane insertion and retrieval of ENaC (70) . In addition, ENaC activity at the membrane depends on other factors, such as CAP-1, a protease that activates ENaC (71; 79). The effect of dexamethasone on the protease activity is however unknown.
Dexamethasone is known to increase ENaC activity by promoting the synthesis of new channels, but also by its activation of sgk, a kinase that has been shown to inhibit ENaC retrieval and degradation (39) to activate silent ENaC at the membrane (20) and to augment ENaC transcription (7). In co-treatment with TNF, dexamethasone was able to increase ENaC channel activity at the membrane to 143%. The decrease of ENaC current at the apical membrane in TNF treated cells was therefore corrected in presence of dexamethasone. As discussed above, this could be related to the compensatory effect of dexamethasone on ENaC current generated at the apical membrane. These data demonstrate that as with ENaC mRNA, TNF and dexamethasone have opposite effects on ENaC activity at the membrane. limiting Na + transport. In TNF+Dex co-treatment, there was no increase of current, but the steroid was able to maintain the current in the normal range. The data presented suggest that amiloride-sensitive-current was maintained within the normal range because steroid treatment was increasing the amount of active ENaC channels at the membrane as reported also in the amphothericin B permeabilization. However there was no further increase in current probably because there was no increased expression of ENaC mRNA compared to and ENaC transcripts in TNF+Dex-treated cells (figure 1).
In apparent contradiction to the amphotericin B data, however, the effect of dexamethasone treatment, although significant (p<0.05), was very modest, with only a 116% increase of ENaC current compared to the untreated controls. The Na + transport process in alveolar epithelial cells is the result of entry of Na + at the apical membrane mainly through ENaC and Na + extrusion by Na + /K + -ATPase at the basolateral side (5; 73). When a normal amount of active ENaC is present at the membrane, however, the basolateral membrane could behave as a rate-limiting step for transepithelial Na + transport. This could explain why in dexamethasone treated cells, although amphotericin B showed increased ENaC current at the apical membrane, the treatment had no significant impact on Na + transepithelial current. This lack of response to dexamethasone could be potentially explained by a lack of stimulation of the different channels, co-transporters or of the Na + /K + -ATPase expressed at the basolateral membrane (60) that are essential to Na + absorption. Na + /K + -ATPase activity is important for Na and enhances lung liquid clearance (24; 76). Dexamethasone has been shown to augment Na + /K + -ATPase activity in alveolar epithelial cells via heightened expression of the 1 subunit (4). Ouabain-sensitive K + uptake is also increased by dexamethasone at 12 h but not at 24 h (4). The absence of dexamethasone stimulation on Na + current reported here could, therefore, also be related to the fact that the measurements were taken after 24 h of treatment. This lack of response to dexamethasone could also be secondary to the lack of stimulation of other channels, like K + channels, which are important for Na + extrusion at the basolateral membrane.
In fact, we reported recently that inhibition of K ATP , KvLQT1 and K Ca channels, present at the basolateral membrane, greatly downregulated amiloride-sensitive transepithelial Na + transport (47). Although dexamethasone had a limited impact on the transepithelial Na + transport, the treatment was effective to normalize amiloride-sensitive Na + current in alveolar cells treated with TNF. Na + transport is essential for the process of liquid absorption in alveolar epithelial cells.
For ENaC activity at the apical membrane was estimated by amphotericin B permeabilization of the basolateral membrane, followed by apical addition of amiloride at a 10-µM final concentration.
TNF treatment decreased the current by 78% (* p<0.05) whereas dexamethasone (Dex) raised it to 198% of the untreated controls (Ctrl)(* p<0.05). Although dexamethasone could increase ENaC current to 143% of the controls in co-treatment with TNF (TNF+Dex), this difference did not reach statistical significance. Amiloride-sensitive current was calculated for 4 independent series (n=4) in each experimental condition. plated from different animals were tested for each experimental condition. 
